Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kurt Wengerter

Vascular Surgery Englewood, NJ Medical Doctor

NPI 1265491880 CMS profile 148592

25 Rockwood Pl, Suite 330, Englewood, NJ 07631

Open in the dashboard

General payments

$6,388

129 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kurt Wengerter of Englewood, NJ is reported in the CMS Open Payments database as having received $6,388 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $424 10
2024 General $343 9
2023 General $883 17
2022 General $675 15
2021 General $1,468 30
2020 General $1,054 18
2019 General $1,542 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kurt Wengerter
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Kurt Wengerter were reported at $424. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Kurt Wengerter Vascular Surgery median Middle half National median
2019 $1,542 $796 $226–$2,363 $163
2020 $1,054 $348 $118–$1,110 $114
2021 $1,468 $471 $158–$1,421 $132
2022 $675 $725 $222–$2,183 $149
2023 $883 $836 $257–$2,440 $160
2024 $343 $909 $252–$2,619 $164
2025 $424 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endologix, Inc. $2,216 15 payments
  2. Boston Scientific Corporation $1,826 42 payments
  3. Medtronic, Inc. $591 17 payments
  4. Bard Peripheral Vascular, Inc. $373 13 payments
  5. W. L. Gore & Associates, Inc. $214 2 payments
  6. Abbott Laboratories $162 6 payments
  7. Next Science LLC $150 2 payments
  8. Smith+Nephew, Inc. $127 5 payments
  9. Organogenesis Inc. $125 1 payment
  10. Cook Medical LLC $114 1 payment
  11. Other $490 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,388 129 payments
Products named General payments · program years 2019–2025
  1. Alto Abdominal Stent Graft System $662 5 payments
  2. General - Vascular Intervention General - Vascular Intervention_PI $559 11 payments
  3. AFX $549 3 payments
  4. Ovation $545 4 payments
  5. GENERAL VASCULAR INTERVENTION $258 8 payments
  6. VENASEAL $185 2 payments
  7. GENERAL - VASCULAR INTERVENTION Vascular $171 4 payments
  8. Xperience $150 2 payments
  9. BlastX $150 2 payments
  10. SurgX $150 2 payments
  11. Other $2,221 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

22

Median for Vascular Surgery: 122

Drug cost

$22,349

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 22 $22,349

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$444,570

Of which drugs: $634

Medicare patients

290

Average age 77

Services billed

7,594

118 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 60%
Chronic kidney disease 59%
Arthritis 52%
Ischemic heart disease 48%
Heart failure 42%
Atrial fibrillation 33%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 76 6,081 $634

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record